Anheuser-Busch InBev, the world’s largest brewer, and Canadian pot producer Tilray Inc. are partnering in a US$100 million joint venture to research cannabis-infused non-alcoholic drinks for the Canadian market, the companies said Wednesday.

The alliance, the latest in a string of deals by global alcohol and tobacco giants in Canada’s cannabis sector, comes amid booming demand for cannabis and a long-term decline in alcohol consumption and smoking.

AB InBev’s Labatt Breweries of Canada, which makes such brands as Blue, 50, Alexander Keith’s, Kokanee and Budweiser, will work with Tilray’s Canadian cannabis subsidiary, High Park Co., which develops and sells cannabis products in Canada, the companies said in a statement.

Canada-listed Harvest Health & Recreation, Inc. announced it won every license it applied to open more retail stores. According to the public cannabis company, each license permit it won allows to open up to three retail stores.

Harvest has cleared the criteria set by the Pennsylvania Department of Health, which issued a total of 23 dispensary permits for Phase II of the medical marijuana program. Harvest will now have six months to become operational before it begins dispensing medical cannabis.

The status of cannabis component CBD as a trendy new superfood ingredient may be cemented this week by U.S. President Donald Trump.

The US$867 billion farm bill, headed to the president for his signature, would remove industrial hemp from a list of federally controlled substances, a major step as weed culture pushes into the U.S. mainstream. That would create a legal market for CBD that could be worth more than US$20 billion by 2022, according to research firm Brightfield Group.

“This is nothing short of seismic for the cannabis industry,” said Kristen Nichols, editor of the trade publication Hemp Industry Daily. “All the obstacles that cannabis faces stem from it being federally illegal.”

Canada is the second sovereign nation to legalize marijuana for adult use, after Uruguay, but it is still grappling with many of the same problems, such as pricing, supply, demand, international activity and the traditional marketplace.

Licensed Canadian growers and producers are hoping to supply European countries, as the United States producers remain frozen out due to Republicans blocking legalization for the past two years.

HTF MI released a new market study on Global Cannabis Chewing Gum Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. The research study provides estimates for Global Cannabis Chewing Gum Forecast till 2025*. Some are the key players taken under coverage for this study are Axim Biotechnologies, Medical Marijuana, Inc. & Plus Gum.

#Summary:

You could rightfully call 2018 a turning point for marijuana stocks. Canada legalized marijuana for recreational use by adults. Michigan became the 10th U.S. state to legalize recreational marijuana, while Missouri and Utah joined the growing club of states that allow medical marijuana. And the November 2018 elections resulted in more representatives in the U.S. Congress who support changes to federal laws regarding marijuana. 

The Privacy Commissioner of Canada released a "guidance document" today explaining why he feels it best that Canadians use cash when purchasing marijuana, even at legal and licensed dispensaries. The guideline also advises Canadians to provide as little personal information as possible when making purchases of marijuana.

Marijuana became legal in Canada this past October, and while most Canadians were more than pleased with the choice by the federal government, there have been a handful of hiccups.

The opening of Canada's recreational marijuana market in October is undeniably big, but the validation of marijuana as medicine could be even more important.

In this clip from The Motley Fool's Industry Focus: Healthcare, analyst Shannon Jones and Todd Campbell discuss why FDA approval of GW Pharmaceuticals (NASDAQ:GWPH)cannabis-derived epilepsy drug was must-know news this year.

Drawing on her background cultivating flowers, the founder of London-area licensed marijuana producer Eve & Co., has now made her company Canada’s first to begin supplying the grow-your-own cannabis market.

It was no easy feat.

Kelsey Jobson, who at the Strathroy-based company deals with provincial pot rules, handled the test shipping runs, using not cannabis plants but citronella.

Tilray has signed a global partnership with a division of Swiss drug giant Novartis to develop and distribute its medical marijuana in legal jurisdictions around the world.

The Canadian pot firm said Tuesday it’s reached an agreement with Sandoz to boost the availability of medical cannabis products globally, building on an existing alliance with Sandoz Canada. The two companies will work together to commercialize Tilray’s non-smokable medical marijuana offerings, co-brand certain products, develop new products and educate pharmacists and physicians about pot.